|Description||BMS 195614 is a neutral RAR α-selective antagonist (Ki = 2.5 nM) and exhibits no significant effect on nuclear receptor corepressor (NCoR) binding. BMS 195614 moderately decreases SMRT binding to RAR and agonist-induced coactivator (CoA) recruitment.|
|Brife Description||RARα antagonist|
|Purity||≥98% by HPLC|
|Synonyms||BMS 195614; BMS195614; BMS-195614; 4-[[[5,6-Dihydro-5,5-dimethyl-8-(3-quinolinyl)-2-naphthalenyl]carbonyl]amino]benzoic acid|
LE 135 is a retinoic acid antagonist which shows moderate selectivity for RARβ over RARα. It can inhibit human HL-60 leukemia cell differentiation induced by Am...
A high affinity pan-RAR antagonist (AGN194310, K(d) for binding to RARs = 2-5 nM) inhibited colony formation (by 50%) by all three lines at 16-34 nM, and led to...
Bexarotene is a retinoid specifically selective for retinoid X receptors, used as an oral antineoplastic agent in the treatment of cutaneous T-cell lymphoma.
Acitretin sodium is a second-generation, systemic retinoid that has been used in the treatment of psoriasis. It can be considered one of the treatments of choic...
ER 50891 is an RARα receptor antagonist (IC50 = 31.2 nM).
AC 261066 is a potent RARβ2 agonist (pEC50 = 8.1).
CD 2665 is a selective RARβ and RARγ antagonist (KD = 110, 306 and > 1000 nM for RARγ, RARβ and RARα respectively) with no activity at RXRα. CD 2665 is used to ...
Adapalene is more active than indomethacin, betamethasone valerate, tretinoin, isotretinoin or etretinate in inhibiting lipoxygease activity, but it has little ...